Separately, Zacks Investment Research raised Neptune Wellness Solutions from a hold rating to a buy rating and set a $3.75 target price on the stock in a research note on Wednesday, March 13th.
NASDAQ:NEPT traded down $0.03 on Wednesday, hitting $3.97. 32,878 shares of the company’s stock traded hands, compared to its average volume of 684,099. Neptune Wellness Solutions has a 1 year low of $2.31 and a 1 year high of $5.14. The stock has a market cap of $317.46 million, a PE ratio of 23.53 and a beta of 1.94.
Neptune Wellness Solutions (NASDAQ:NEPT) (TSE:NTB) last released its earnings results on Wednesday, February 13th. The biotechnology company reported ($0.04) earnings per share for the quarter. Neptune Wellness Solutions had a negative net margin of 60.48% and a negative return on equity of 18.85%. The business had revenue of $4.95 million for the quarter. Sell-side analysts forecast that Neptune Wellness Solutions will post -0.06 EPS for the current year.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Deutsche Bank AG grew its stake in shares of Neptune Wellness Solutions by 245.9% in the 4th quarter. Deutsche Bank AG now owns 517,135 shares of the biotechnology company’s stock valued at $1,313,000 after buying an additional 367,614 shares in the last quarter. Morgan Stanley grew its stake in shares of Neptune Wellness Solutions by 19.5% in the 1st quarter. Morgan Stanley now owns 191,619 shares of the biotechnology company’s stock valued at $611,000 after buying an additional 31,225 shares in the last quarter. Two Sigma Advisers LP bought a new stake in shares of Neptune Wellness Solutions in the 4th quarter valued at approximately $367,000. Alpine Group USVI LLC bought a new stake in shares of Neptune Wellness Solutions in the 1st quarter valued at approximately $303,000. Finally, Renaissance Technologies LLC grew its stake in shares of Neptune Wellness Solutions by 696.0% in the 3rd quarter. Renaissance Technologies LLC now owns 93,654 shares of the biotechnology company’s stock valued at $363,000 after buying an additional 81,889 shares in the last quarter. 14.49% of the stock is owned by institutional investors and hedge funds.
Neptune Wellness Solutions Company Profile
Neptune Wellness Solutions Inc, a health and wellness products company, specializes in the extraction, purification and formulation of cannabis products, as well as other specialty ingredients, such as MaxSimil, a patented ingredient that enhances the absorption of lipid-based nutraceuticals, and various other marine and seed oils.
Featured Article: How is Preferred Stock Different from Common Stock?
Receive News & Ratings for Neptune Wellness Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neptune Wellness Solutions and related companies with MarketBeat.com's FREE daily email newsletter.